Table 3.
Treatment patterns of nab-paclitaxel initiators by line of therapya
| Variable | First line (n = 172) | Second line (n = 211) | Third or later line (n = 281) | All (N = 664) | ||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| Treatment regimen | ||||||||
| Monotherapy | 109 | 63.4 | 129 | 61.1 | 167 | 59.4 | 405 | 61.0 |
| Combination chemotherapy | 63 | 36.6 | 82 | 38.9 | 114 | 40.6 | 259 | 39.0 |
| Bevacizumab | 51 | 81.0 | 53 | 64.6 | 45 | 39.5 | 149 | 57.5 |
| Trastuzumab or lapatinib | 3 | 4.8 | 14 | 17.1 | 45 | 39.5 | 62 | 23.9 |
| Gemcitabine, carboplatin, pegylated liposomal doxorubicin/doxorubicin, docetaxel, doxorubicin, paclitaxel, irinotecan, vinorelbine, or 5-fluorouracil | 3 | 4.8 | 8 | 9.8 | 14 | 12.3 | 25 | 9.7 |
| ≥ 2 agents from above list | 6 | 9.5 | 7 | 8.5 | 10 | 8.8 | 23 | 8.9 |
| Treatment scheduleb | 152 | 193 | 260 | 605 | ||||
| Weekly | 114 | 75.0 | 134 | 69.4 | 180 | 69.2 | 428 | 70.7 |
| q3w | 38 | 25.0 | 59 | 30.6 | 80 | 30.8 | 177 | 29.3 |
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| Duration of line treatment, d | 159.0 | (83.0–241.0) | 119.0 | (65.0–191.0) | 122.0 | (76.0–191.0) | 128.0 | (76.0–199.0) |
| Initial dose, unitc | 200.0 | (200.0–429.0) | 200.0 | (200.0–400.0) | 200.0 | (200.0–400.0) | 200.0 | (200.0–400.0) |
| Average dose, unitc | 227.5 | (200.0–394.4) | 220.0 | (200.0–400.0) | 214.9 | (200.0–400.0) | 218.5 | (200.0–400.0) |
IQR interquartile range, q3w every 3 weeks
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
b59 patients (20 in first-line, 18 in second-line, and 21 in third-line or later therapy) could not be classified into a weekly or q3w treatment schedule
cEach unit is equivalent to 1 mg. The dosage calculated may not reflect the exact dose dispensed or received